Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Targets 5 Percent Annual Sales Increase In North America

This article was originally published in PharmAsia News

Executive Summary

Japan's second largest drug maker Astellas is optimistic about sales growth in the North American market. The company aims to achieve an annual 5 percent increase and estimates a strong demand for the overactive bladder drug Vesicare (solifenacin), Astellas U.S. President Yoshihiko Hatanaka said during a Tokyo briefing Aug. 28. According to Hatanaka, the U.S. market for Vesicare is estimated to grow 44 percent to $349 million in 2008. The strong growth could help offset estimated decreased sales in Astellas' blockbuster immunosuppressant Prograf (tacrolimus), which has gone off-patent in the U.S. (Click here fore more - Japanese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts